ArticleAntimicrobial agents and chemotherapy2006
Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- EneA of Aspergillus fumigatus is a regulator of secondary metabolism and enhances nscA expression in presence of polyenes and Streptomyces.Scientific reports · 2026Article
- Decoding Pecan's Fungal Foe: A Genomic Insight intoJournal of fungi (Basel, Switzerland) · 2025Article
- Transcriptome Analysis of Human Dermal Cells Infected with Candida auris Identified Unique Pathogenesis/Defensive Mechanisms Particularly Ferroptosis.Mycopathologia · 2024Article
- Farnesol Boosts the Antifungal Effect of Fluconazole and Modulates Resistance inJournal of fungi (Basel, Switzerland) · 2022Article
- Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.mSphere · 2022Article
- Genomic Variation-Mediating Fluconazole Resistance in Yeast.Biomolecules · 2022Review
- Palmarumycin P3 Reverses Mrr1-Mediated Azole Resistance by Blocking the Efflux Pump Mdr1.Antimicrobial agents and chemotherapy · 2022Article
- The evaluation of the overexpression of the ERG-11, MDR-1, CDR-1, and CDR-2 genes in fluconazole-resistant Candida albicans isolated from Ahvazian cancer patients with oral candidiasis.Journal of clinical laboratory analysis · 2022Article
- Does Systemic Methotrexate Therapy Induce Azole Resistance among EndogenousAntibiotics (Basel, Switzerland) · 2021Article
- Cyano- and Ketone-Containing Selenoesters as Multi-Target Compounds against Resistant Cancers.Cancers · 2021Article
- Mrr1 regulation of methylglyoxal catabolism and methylglyoxal-induced fluconazole resistance in Candida lusitaniae.Molecular microbiology · 2021Article
- Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana.Folia microbiologica · 2020Article
- Quantitative analysis of the expression of fluconazole-resistant genes in strains of Candida albicans isolated from elderly people at their admission in an intensive care unit in Manizales, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Antifungal Styryloquinolines asMolecules (Basel, Switzerland) · 2020Article
- Synthesis of new piperazinyl-pyrrolo[1,2-RSC advances · 2020Article
- Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance inFrontiers in cellular and infection microbiology · 2020Article
- MFS transporter from Botrytis cinerea provides tolerance to glucosinolate-breakdown products and is required for pathogenicity.Nature communications · 2019Article
- Evolution of drug resistance in an antifungal-naive chronicProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Host-Pathogen Interactions Mediated by MDR Transporters in Fungi: As Pleiotropic as it Gets!Genes · 2018Review
- Regulation of Hyphal Growth and N-Acetylglucosamine Catabolism by Two Transcription Factors inGenetics · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of MDR1, which encodes a membrane transport protein of the major facilitator superfamily, is one mechanism by which the human fungal pathogen Candida albicans can develop increased resistance to the antifungal drug fluconazole and other toxic compounds. In clinical C. albicans isolates, constitutive MDR1 overexpression is accompanied by the upregulation of other genes, but it is not known if these additional alterations are required for Mdr1p function and drug resistance. To investigate whether MDR1 overexpression is sufficient to confer a drug-resistant phenotype in C. albicans, we expressed the MDR1 gene from the strong ADH1 promoter in C. albicans laboratory strains that did not express the endogenous MDR1 gene as well as in a fluconazole-resistant clinical C. albicans isolate in which the endogenous MDR1 alleles had been deleted and in a matched fluconazole-susceptible isolate from the same patient. Forced MDR1 overexpression resulted in increased resistance to the putative Mdr1p substrates cerulenin and brefeldin A, and this resistance did not depend on the additional alterations which occurred during drug resistance development in the clinical isolates. In contrast, artificial expression of the MDR1 gene from the ADH1 promoter did not enhance or only slightly enhanced fluconazole resistance, presumably because Mdr1p expression levels in the transformants were considerably lower than those observed in the fluconazole-resistant clinical isolate. These results demonstrate that MDR1 overexpression in C. albicans is sufficient to confer resistance to some toxic compounds that are substrates of this efflux pump but that the degree of resistance depends on the Mdr1p expression level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.